Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

33.07
+1.213.80%
Post-market: 33.070.00000.00%16:20 EDT
Volume:2.16M
Turnover:71.11M
Market Cap:5.26B
PE:-11.03
High:33.36
Open:32.26
Low:31.70
Close:31.86
Loading ...

Tryngolza™ (Olezarsen) Approved in U.S. as First-Ever Treatment for Adults Living With Familial Chylomicronemia Syndrome as an Adjunct to Diet

THOMSON REUTERS
·
20 Dec 2024

Ionis Pharmaceuticals Inc - Tryngolza to Be Available in U.S. Before Year End

THOMSON REUTERS
·
20 Dec 2024

BRIEF-FDA Approves Ionis Pharmaceuticals' Olezarsen For Familial Chylomicronemia Syndrome- Website

Reuters
·
20 Dec 2024

US FDA approves Ionis Pharma's genetic disorder drug

Reuters
·
20 Dec 2024

FDA Approves Ionis Pharmaceuticals' Olezarsen for Familial Chylomicronemia Syndrome- Website

THOMSON REUTERS
·
20 Dec 2024

Ionis Pharmaceuticals trading halted, news pending

TIPRANKS
·
20 Dec 2024

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

Zacks
·
13 Dec 2024

How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%

Zacks
·
11 Dec 2024

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Zacks
·
07 Dec 2024

Theratechnologies Acquires Canadian Rights to 2 RNA Medicines From Ionis Pharmaceuticals

MT Newswires Live
·
04 Dec 2024

Theratechnologies enters exclusive licensing agreement with Ionis

TIPRANKS
·
04 Dec 2024

Ionis Pharmaceuticals Inc : Raymond James Adds Stock to Its Analyst Current Favorites List

THOMSON REUTERS
·
02 Dec 2024

Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)

TIPRANKS
·
28 Nov 2024

Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
28 Nov 2024

Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?

Insider Monkey
·
22 Nov 2024

Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now

Insider Monkey
·
20 Nov 2024

LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study

Zacks
·
20 Nov 2024

Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks

Zacks
·
18 Nov 2024

Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
14 Nov 2024